Immunoglobulin superfamily (IgSF) domains are conserved structures present in many proteins in eukaryotes and prokaryotes. These domains are well-capable of facilitating sequence variation, which is most clearly illustrated by the variable regions in immunoglobulins (Igs) and T cell receptors (TRs). We studied an antibody-deficient patient suffering from recurrent respiratory infections and with impaired antibody responses to vaccinations. Patient's B cells showed impaired Ca 21 influx upon stimulation with anti-IgM and lacked detectable CD19 membrane expression. CD19 sequence analysis revealed a homozygous missense mutation resulting in a tryptophan to cystein (W52C) amino acid change. The affected tryptophan is CONSERVED-TRP 41 located on the C-strand of the first extracellular IgSF domain of CD19 and was found to be highly conserved, not only in mammalian CD19 proteins, but in nearly all characterized IgSF domains. Furthermore, the tryptophan is present in all variable domains in Ig and TR and was not mutated in 117 Ig class-switched transcripts of B cells from controls, despite an overall 10% amino acid change frequency. In vitro complementation studies and CD19 western blotting of patient's B cells demonstrated that the mutated protein remained immaturely glycosylated. This first missense mutation resulting in a CD19 deficiency demonstrates the crucial role of a highly conserved tryptophan in proper folding or stability of IgSF domains.
INTRODUCTION
Antibody deficiencies form the largest group of primary immunodeficiencies and patients present either in early childhood or in adulthood with increased susceptibility to mainly bacterial infections due to a defective antibody response (1, 2) . Over the past two decades, multiple genetic defects have been found to underlie an antibody deficiency syndrome (2) .
Patients with mutations in the CD19 (MIM 107265) and CD81 (MIM 186845) genes have reduced immunoglobulin (Ig) serum levels, reduced memory B cell numbers and impaired antibody responses to vaccinations (3 -5) . On mature B cells, CD19, CD81, CD21 and CD225 form the CD19 complex that signals in conjunction with the B cell antigen receptor (BcR), thereby decreasing the threshold for BcR-dependent signalling (6 -8) . CD19 contains two extracellular immunoglobulin superfamily (IgSF) constant (C) domains ([D1] and [D2]), one transmembrane region and a cytoplasmic region with nine tyrosine residues, two of which are critical for downstream signalling, Y500 and Y531 (9) . All six described CD19-deficient patients have mutations that lead to a premature stop codon upstream of the critical tyrosines and result in loss of CD19 membrane expression (3, 4, 10, 11) . One patient has been identified with a CD81 splice site mutation resulting in a premature stop codon and loss of CD81 and CD19 expression (5) . Owing to the truncated CD81 protein, B cells of this patient appeared unable to transport the unmutated CD19 protein to the cell membrane, demonstrating the critical role of CD81 for CD19 expression. It remains unclear whether missense mutations in these genes can lead to defective proteins and result in a primary antibody deficiency.
IgSF domains are evolutionary highly conserved structures that are present in many proteins and belong to two structural types: V and C that differ by the number of antiparallel b-strands, nine and seven, respectively (12, 13) . These strands are positioned in two b-sheets that form a barrel-like shape through a disulphide bridge between two cysteines in the B-strand (1st-CYS 23) and the F-strand (2nd-CYS 104) (12 -14) . A conserved tryptophan (CONSERVED-TRP 41) in the C-strand packs the disulphide bridge and forms a structural motif with the two cysteine residues and portions of six other residues (positions 21, 22, 87, 88, 89 and 103), called the pin (15) . Despite the high structural conservation, the various IgSF domains throughout different proteins and between homologous proteins from different species show high sequence variability. The greatest variability is observed in the variable domains of Ig and T cell receptors (TRs) (16) . These can be encoded by multiple IGHV genes (17) , which are highly variable in the loops or complementarity-determining regions (CDRs) connecting the b-sheets, and also in the residues that make up the b-sheets themselves or framework regions (FRs) (18, 19) . Still, all productive V domains of Igs and TRs contain the two conserved cysteines and the single tryptophan of the pin structure (18, 19) .
We identified a CD19 deficiency in a 6-year-old boy who suffered from an antibody-deficiency syndrome due to defective BcR signalling. The absence of CD19 molecules on the patient's B cells was caused by a missense mutation resulting in an amino acid change in [D1]. The affected residue was the conserved tryptophan of the pin structure, which was mutated into a cysteine. The mutant protein was immaturely glycosylated in the endoplasmic reticulum, probably due to incorrect folding. To our knowledge, this is the first CD19 deficiency due to a missense mutation in the CD19 gene. The mutation underlines the critical role of the tryptophan residue in the pin structure of IgSF domains that are otherwise well capable of incorporating many different changes in amino acid sequence.
RESULTS

Case report
A Moroccan 6-year-old boy suffering from repeated upper and lower respiratory tract infections and a Streptococcus pneumoniae septicemia was referred for immunological investigation (patient ID604). His parents are first cousins and are in good health as is his 2-year-old sister. The physical examination was without particularity but blood sample analysis revealed a hypogammaglobulinaemia. Allohaemagglutinin titre was low (1/4 anti-A; blood group B) and there was no antibody response to a tetanus toxoid vaccine booster. The evaluation of the complement system was normal. The child was successfully treated with intravenous Igs first, replaced later by subcutaneous Igs. No severe infections were noted since the start of the Ig substitution therapy.
Blood lymphocyte and B cell subset analysis
Flow cytometric analysis of the patient's blood sample showed normal frequencies and absolute numbers of lymphocyte subsets (T, B, NK cells) when compared with healthy controls (Table 1) . Despite normal total B cell numbers, the patient showed reduced numbers of transitional B cells and both IgD+ and IgD2 memory B cells. Moreover, all B cells lacked CD19 membrane expression (Fig. 1A) .
Homozygous missense mutation in the CD19 gene
To identify the underlying genetic defect, all coding exons of the CD19 gene were PCR-amplified and sequenced from . Carriership analysis was performed in several family members of the patient. Both parents were found to be heterozygous for the mutation, whereas a younger sister of the patient did not carry the (12, 13) . (C) Pedigree of the family. The patient was born to consanguineous parents who were both heterozygous carriers of the missense mutation. One sister did not carry the mutation. (D) Expression levels of CD19 complex members on B cells of the patient (ID604), a carrier of the mutation (ID604A) and a wild-type control. CD19 was absent on patient's B cells and reduced on B cells from a carrier. CD21 expression levels were reduced on B cells of the patient and the carriers, whereas CD81 and CD225 were normally expressed. Isotype controls are shown for CD81 and CD225 stains and CD202 negative lymphocytes for CD19 and CD21 stains.
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Human Molecular Genetics, 2011, Vol. 20, No. 9 mutation (Fig. 1C ). These observations fit with current ideas that CD19 deficiency is an autosomal recessive disorder. However, previously identified CD19 gene mutations introduced premature stop codons or an entire gene deletion, resulting in truncated proteins lacking important tyrosines in the cytoplasmic region (3, 4, 11) .
Expression of CD19 complex members
To study the effects of the c.156G.C mutation on CD19 protein formation, we determined the expression levels of CD19 complex members on B cells of the patient, family members and healthy controls. CD19 was not present on B cells of the patient and reduced on B cells of carriers when compared with healthy controls (Fig. 1D) . Furthermore, CD21 expression levels were reduced on B cells from the patient and carriers, whereas CD81 and CD225 were normally expressed. These observations from the patient and carriers of the mutation strongly suggests that the CD19 protein encoded by the allele with the c.156G.C mutation is not expressed on the surface membrane of B cells (4, 10) .
BcR signalling
To determine the effects of CD19 complex disruption on BcR signalling in B cells of our patient, we performed Ca 2+ flux analysis upon stimulation with anti-IgM. When compared with healthy controls, the patient's B cells showed a delayed Ca 2+ influx from the rough endoplasmic reticulum into the cytoplasm (Fig. 2) . The following increase in baseline Ca 2+ levels was similar to healthy controls. These results were similar to previously described patients with a premature stop codon in exon 11 of CD19 (4) and demonstrate a B cell intrinsic defect in our patient.
Somatic hypermutation
To gain insight into the molecular signs of immunological memory, we studied the somatic hypermutation (SHM) frequency in Ig class-switched transcripts of the few blood memory B cells. The majority of VH-Ca and VH-Cg transcripts of the patient contained SHM. However, the mutation rate per transcript was greatly reduced from, on average, 6 -7% in controls to ,2% (Fig. 3A) . Further analysis was carried out on the frequency and pattern of amino acid changes. As expected, this revealed high mutation frequencies in the CDR-IMGT when compared with the FR-IMGT regions for transcripts of healthy controls (Fig. 3B ). In addition, several positions in FR3 were frequently mutated as well (.20% of transcripts). The overall amino acid change rate was drastically reduced in transcripts of the patient. The mutation pattern was quite similar to that of healthy controls with higher mutation frequencies in CDR1 and CDR2, but lacked high mutation frequencies of residues in FR3 (Fig. 3B) . Thus, the SHM analyses on DNA and protein level showed comparable patterns between the patient and healthy controls, but total frequencies were strongly reduced, fitting with the impaired humoral immune responses in the patient.
Functional B and T cell responses
The in vitro lymphocyte proliferation to mitogens (phytohaemagglutinin and pokeweed mitogen) and to antigens (tetanus toxoid and candidin) was normal to high (not shown). In contrast, whereas antigen-specific IgG-secreting cells are normally detected in the circulation 7-9 days after the administration of a parenteral vaccine (20) , no anti-tetanus toxoid or anti-pneumococcal IgG-secreting cells were detected among the PBMC from the patient, less than 10 spots/10 6 PBMC being usually considered the background level (Table 2) . Furthermore, the numbers of total IgG-and IgA-secreting cells were very low, the number of IgG-secreting cells being similar to the background (Table 2) .
Thus, the clinical and immunological features of our patient in combination with the functional defect in BcR signalling strongly suggest that the antibody deficiency in our patient is B cell intrinsic and caused solely by the CD19 missense mutation.
In vitro complementation of the CD19 deficiency
To prove that impaired CD19 membrane expression in the patient's B cells is solely due to the W52C replacement, we reconstituted EBV immortalized B cells of the patient with retroviral constructs containing wild-type CD81, wild-type CD19 or mutated CD19. Whereas over-expression of CD81 did not restore CD19 expression, introduction of wild-type CD19 did (Fig. 4A) . The patient's B cells are therefore able to express wild-type CD19 on the surface membrane. Overexpression of CD19 containing the W52C replacement, however, did not result in membrane expression. Thus, the absence of CD19 membrane expression is directly caused by the c.156G.C mutation that introduces the W52C replacement.
CD19 was not detected on the membrane of the patient's B cells, using antibodies that recognize extracellular epitopes. Theoretically, it is possible that CD19 is expressed, but cannot be recognized by these antibodies due to alternative folding. All extracellular CD19 antibodies react with the same epitope (21) . Therefore, we studied CD19 expression in EBV B cells of the patient, using an antibody that recognizes an intracellular epitope. In contrast to EBV B cells from patient ID037 that lack the complete cytoplasmic CD19 region (4), cytoplasmic CD19 was normally expressed in cells from patient ID604 (this paper; Fig. 4B ). From these results it remains unclear whether the detected CD19 is 
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expressed on the membrane or in an intracellular compartment. Therefore, we performed western blotting using the same CD19 antibody that recognizes an intracellular epitope. We were able to detect some CD19 protein in EBV B cells of the patient (Fig. 4C) . However, the amount of protein was reduced when compared with controls. Moreover, the molecular weight was clearly smaller and similar to that of wild-type CD19 in CD81-deficient EBV B cells. In the absence of CD81, CD19 has been shown to be immaturely glycosylated and retained in the ER (5). Thus, the W52C replacement probably leads to impaired processing of CD19 in the ER. However, considering the amount of CD19 protein, it is still possible that some CD19 is expressed on the membrane, but undetectable by extracellular antibodies due to the mutation.
Mutated W52 corresponds to CONSERVED-TRP 41 in IgSF domains
The impact of the W52C replacement on CD19 expression suggests a crucial role for the W52 in proper protein folding and stability. Multiple sequence alignment of CD19 proteins from several mammals demonstrated conservation of the tryptophan in [D1] (Fig. 5A) . Moreover, secondary structure prediction and comparison with the 60% consensus sequence of C domains showed that the affected tryptophan is CONSERVED-TRP 41 in the C-strand that shields the disulphide bridge. It is one of only nine unique amino acids in the 60% consensus sequence (Fig. 5A) . Two of the other residues concern the cysteines in the second and sixth b-strands that are required for the folding of the seven b-strands of a C domain into a barrel that is characteristic of IgSF domains (Fig. 5B) . The V domains of Ig heavy and Ig light chains are highly similar in structure to the C domains of CD19. Despite high sequence variability of these V domains, they all form this barrel structure. The C-strand of Ig V domains is encoded by IGHV genes and all .140 functional IGHV genes of the three Ig loci contain this tryptophan in their FR2-IMGT at position 41 (W41) (22) . Furthermore, none of the 157 analysed VH-Ca and VH-Cg transcripts from controls and the patient was mutated at position 41 (Fig. 3B ). Since we found amino acid changes in nearly all positions including residues flanking W41, we concluded that these transcripts were selected against amino acids changes of W41. Thus, W41 in the C-strand is highly conserved in both V and C domains underlying a crucial role in proper folding and stability of the IgSF domain barrel structure.
DISCUSSION
We report on an antibody-deficient patient born to consanguineous parents. He presented with recurrent infections and reduced serum IgM and IgG levels. Immunological work-up demonstrated low iso-haemagglutinin titres and impaired specific antibody production upon vaccinations, reduced memory B cells with low SHM levels and a B cell intrinsic defect in signalling via the BCR. Our studies demonstrate that a homozygous missense mutation in CD19 causes the absence of membrane CD19 expression. The affected residue concerned a highly conserved tryptophan in the first extracellular IgSF domain of CD19, and the mutant protein remained immaturely glycosylated.
Early recognition of antibody deficiencies and identification of underlying genetic defects form the basis for adequate treatment, monitoring of complications and estimation of prognosis. However, one has to be careful with concluding whether an identified mutation is pathogenic or not (23, 24) . In our patient, we identified a homozygous missense mutation in the CD19 gene after we found no CD19 expression on his B cells. Based on multiple immunological, bioinformatics and functional studies, we concluded that the mutation is diseasecausing: (i) the clinical and immunological presentation of the patient was similar to previously described CD19-complex-deficient patients (3 -5,10); (ii) CD19 expression was reduced in carriers of the mutation; (iii) CD81 is critical for CD19 expression and was normally expressed (5); (iv) CD19 expression could be restored in patient's B cells with a wild type, but not a mutant CD19 construct; (v) the mutation affected the tryptophan residue (W41) that is highly conserved in mammalian CD19 proteins and in most of the identified IgSF domains; (vi) the mutated CD19 protein was retained in the ER/early Golgi in B cells of the patient.
Despite their conserved structural organization, IgSF domains are well capable of facilitating many different changes in the amino acid sequence. This is employed for the V domains by the immune system, where B cells assemble Ig V domains from multiple coding genes during V-(D)-J recombination in the bone marrow. The Ig V domains are mutated upon antigen-recognition via SHM in secondary lymphoid origins. Still, all functional IGHV genes contain the conserved tryptophan 41 (19) , and this residue was not mutated in 117 analysed Ig class-switched transcripts.
Several IgSF domains have been characterized without the conserved W41: in b2-microglobulin and CD7, it has been replaced by a leucine. These replacements introduced other hydrophobic residues, but resulted in a reduction of side chain volume that had to be filled. Apparently, this has been possible, probably as a result of additional changes in other positions and reorientation of side chains (25, 26) . These Antibody-secreting cells were measured 7 days after the vaccine boosters.
modifications are rare and thus not favourable for IgSF V and C domains. Furthermore, W41C amino acid change in CD19 of our patient introduces an even smaller residue with a highly reactive sulphhydryl group and probably impairs folding of the hydrophobic pocket. We identified the first missense mutation causing a CD19 deficiency. The six other reported CD19 mutations concerned insertions and deletions (3, 4, 11) . Although only few mutations have been reported, the incidence of missense mutations causing CD19 deficiency appears low. Mutations in BTK and CD40LG are the most common causes of antibody deficiency (1, 2) . Over 600 BTK mutations (27) , and over 150 CD40LG mutations, have been reported in the human genome mutation database (HGMD) (28), of which 33 and 26% are caused by missense mutations, respectively. As these proteins are composed of different structural domains than CD19 and they lack IgSF domains, the flexibility for incorporation of missense mutations could depend on the structural domains in proteins. Mutations in IGHM, CD79A and CD79B can cause agammaglobulinaemia (29) (30) (31) (32) . These are components of the pre-BcR, and, similar to CD19, these contain one (CD79A and CD79B) or four (IGHM) IgSF domains. Including this study, 25 mutations in IGHM (MIM 147020), CD79A (MIM 112205), CD79B (MIM 147245) and CD19 have been reported, of which only 3 are missense mutations: 1 in IGHM, 1 in CD79B and 1 in CD19 (3,4,11,29-37) . Thus, the high flexibility for incorporation of sequence variations of IgSF domains could underlie the low frequency of missense mutations disrupting protein function in these genes. Considering the low number of invariant amino acids in IgSF domains, missense mutations will probably be underrepresented in CD19 deficiency.
In this study, we reported the first CD19 deficiency in an antibody-deficient patient due to a missense mutation (W52C). The clinical and immunological findings are in line with previously reported CD19-deficient patients and will support establishment of a homogeneous subgroup within the diverse spectrum of antibody deficiencies. The complete CD19 deficiency in our patient underlines the crucial role of CONSERVED-TRP 41 in proper folding of IgSF domains.
MATERIALS AND METHODS
Diagnostic work-up of blood and vaccinations were carried out after the approval of the Commission d'Ethique Médicale from the Queen Fabiola Children's University Hospital in Brussels, and informed consent of the child's parents.
Flow cytometry and Ca 21 flux analysis
Six-colour flow cytometric immunophenotyping of blood samples from the patient, 3 relatives and 17 healthy childhood controls was performed to analyse leucocyte subsets and protein expression. The following monoclonal antibodies were used: CD5-APC (L17F12), CD19-FITC (HIB19), CD19-PE (4G7), CD19-APC (SJ25C1), CD20-APC-Cy7 (L27), CD27-APC (L128), CD38-PE-Cy7 (HB7), CD81-APC (JS81), IgD-PE (all from BD Biosciences) and CD24-FITC (IB5; Sanquin). Ca 2+ fluxes upon BCR stimulation were performed in CD20-positive B lymphocytes by flow cytometry as described before (4) . B cells were stimulated with Staphylococcus aureus Cowan I (SAC; Calbiochem), diluted 1:500, or with 
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Human Molecular Genetics, 2011, Vol. 20, No. 9 ′ ) 2 (Jackson ImmunoResearch Laboratories, Inc.). Subsequently, 2 mg/ml ionomycin (Molecular Probes) was added after each response to control for intracellular loading of Indo-1.
Antigen-specific antibody responses
Serum anti-tetanus toxoid IgG levels and anti-pneumococcal IgG and IgA levels were measured by ELISA methods as described previously (20, 38, 39) . The response to vaccine administrations was evaluated at the cellular level by an Elispot technique as described previously to avoid any interference of the Igs that were already administrated at that time (5) .
In vitro T cell responses
Lymphocyte proliferation was evaluated after culture in the presence of mitogens for 3 days (phytohaemagglutinin and pokeweed mitogen), or antigen for 6 days [tetanus toxoid: 5 mg/ml (Statens Serum Institut) or candidine: 5 IU/ml 
SHM analysis
Total cDNA was prepared from mRNA isolated from mononuclear cells of the patient as described previously (40) . Hypermutation was studied in VH3-Ca, VH4-Ca, VH3-Cg and VH4-Cg fragments, amplified from PBMC cDNA and cloned into pGEM-T easy vector (Promega, Madison, WI, USA). Nomenclature of IMGT w , the international ImMunoGeneTics information system w (http://www.imgt.org/) and the IMGT/V-QUEST tool were used to assign the IGHV, IGHD and IGHJ genes and to identify SHM (41, 42) . The mutation frequency was determined for the IGHV gene of each transcript. Furthermore, we studied the replacement/ silent ratio of these mutations for FR-IMGT and CDR-IMGT, and the distribution of replacement mutations in FRs was analysed according to the binomial distribution model of Chang and Casali (43). 
CD19 mutation analysis
All exons of the CD19 gene (NCBI_AB052799) were PCR-amplified using DNA isolated from post-Ficoll granulocytes of the patient and sequenced on an ABI Prism 3130 XL fluorescent sequencer (Applied Biosystems) (4). Carriership analysis was performed in both parents and the sister of the patient by specific amplification and sequencing of exon 2.
EBV transformation and retroviral transduction
Immortalization of patient's and control B cells with EBV derived from supernatant of the B95 -8 cell line was performed as described before (5) . Wild-type human CD19 and CD81 cDNA (Open Biosystems) and mutant CD19 (generated by site-directed mutagenesis; Stratagene) were cloned into retroviral LZRS-IRES-Lyt2a or LZRS-IRES-eGFP vectors. The LZRS-IRES constructs were transfected into the Phoenix amphotropic packaging cell lines, using Fugene-6 (Roche Molecular Biochemicals). Stable high-titre producer clones were selected with puromycin (1 mg/ml) (44) . The EBVtransformed B cell lines were cultured for several days in RPMI 1640 medium containing 10% FCS and antibiotics before transduction using Retronectin-coated Petri dishes (Takara) and recombinant retrovirus containing supernatant for 2 days. Transduced cells were identified by eGFP expression (CD81 construct) or mouse CD8a expression (Lyt2a; CD19 constructs).
Intracellular CD19 detection
Cytoplasmic CD19 was detected in EBV B cells following cell fixation and permeabilization (An der Grub GMBH) with polyclonal rabbit antiserum against the intracellular region of human CD19 (Cell Signaling Technology) and FITCconjugated polyclonal goat-anti-rabbit antibodies as the second-step reagent.
Lysates of 10 6 EBV B cells were separated by sodium dodecyl sulphate -polyacrylamide gel electrophoresis and immunoblotted with the use of a polyclonal rabbit antiserum against the intracellular region of human CD19 (Cell Signaling Technology) and mouse anti-human actin (Abcam). Secondary stains were performed with anti-rabbit IRDye 800CW and anti-mouse IRDye 680 prior to detection on an Odyssey imaging system (LI-COR Biosystems).
IgSF domain analysis
Multiple sequence alignments of CD19 protein sequences of human (Homo sapiens; RefSeq NM_001770.5), Rhesus monkey (Macaca mulatta; RefSeq XM_001103043.1), pig (Sus scrofa; RefSeq NM_214377.1), rat (Rattus norvegicus; RefSeq NM_001013237.2) and mouse (Mus musculus; RefSeq NM_009844.2) were created with the Clustal W algorithm (45) . Subsequently, the multiple sequence alignment of the first CD19 IgSF C domain was compared with the 60% consensus sequence derived from the Simple Modular Architecture Research Tool (SMART) (46) . Finally, the Jpred 3 secondary structure prediction server was used to assign amino acids present in b-strand topology (47) .
